Professional Resources
Use these resources to find helpful information on TORISEL, advanced renal cell carcinoma (RCC) treatment, clinical trials, patient support, practice management, and more.
- Reprint Library
Downloadable articles:- Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine. 2007;356:2271-2281.
- Mekhail TM, Abou-Jawde RM, BouMerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. Journal of Clinical Oncology. 2005;23:832-841.
- Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. Journal of Clinical Oncology. 2002;20:289-296.
- Professional Web Sites
Web site listings for clinical trials, professional guidelines and associations, journals, CME, and government organizations - TORISEL Interactive Review
Participate in an interactive review of the published TORISEL phase 3 clinical trial - Conferences and Events
Upcoming conferences and events about oncology
- Renal Cell Carcinoma (RCC) Overview
Renal cell carcinoma epidemiology, histology, and staging information
Wyeth Oncology Portal
Wyeth is committed to the discovery and development of novel, targeted cancer therapies, and to providing health care professionals with information and resources that may be helpful in using these therapies.
242252-01